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Treatment with statins is known all over the world. They are generally considered safe at therapeutic doses. Nevertheless, 
clinical trials are not enough to assess their scarce adverse effects such as idiosyncratic drug induced liver injury (DILI). 
Due to some conditions, such as concomitant usage (drug-drug interaction using an identical metabolising enzyme) and 
genetic polymorphisms, there is an increasing concern about their safety. Hepatotoxicity and rhabdomyolysis have begun 
to appear in published studies. Most of investigations have focused on both these adverse effects and mechanisms of drug 
induced toxicity. The present review has attempted to compile almost all of the existing studies on the hepatotoxicity of 
statins but not rhabdomyolysis. The aim of our study is to provide an overview of the studies on the statin-associated 
hepatotoxicity and to discuss the published studies. The researchers are of the opinion that the research on this topic is 
incomplete but extremely necessary.
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Drug-induced liver injury (DILI) is a major complication 
with many drugs. Drug induced acute hepatic injury occurs 
in 5 to 10 % of patients hospitalised for jaundice (1-4). 
Furthermore, drugs are the most common cause of fulminant 
hepatic failure, both in the United States and Europe (5, 6). 
In the reports from the United States and Sweden, 
idiosyncratic drug reactions (IDRs) were the hypothetical 
reasons in 13 % of the cases of acute liver failure (ALF) in 
the USA and 1 % in Sweden (5, 7). The prognosis for 
patients with ALF due to IDRs is usually poor. Without 
liver transplantation, mortality rates can be as high as 60- 
80 % (8, 9). During the last decade, DILI has led to 
withdrawal of a number of drugs from the market (10-14). 
Reports on the frequency of adverse reactions involving 
statins indicate 4.2 % of cases in New Zealand, 1.4 % in 
France, 5.9 % in Denmark, 1.4 % in India, and about 10% 
in the United States (15-17). Hepatocellular injury and 
jaundice resulting from the administration of different drugs 
(such as isoniazid 10 % and halothane 50 %) lead to a 
mortality rate of 10 to 50 % (11-13). This phenomenon is 
known as “Hy’s rule”. According to the rule, both drug-
induced hepatocellular (HC) injury and jaundice occur at 
the same time without biliary obstruction and 10 % 
mortality can be anticipated (11, 13, 14). Hy’s rule is defined 
as DILI with serum alanine aminotransferase (ALT) levels 
3 or more times the upper limit of normal (ULN) and serum 
bilirubin levels 2 or more times the ULN. It has been used 
to assess the hepatotoxicity of newly developed drugs and 
is encouraged by the U.S. Food and Drug Administration 
(FDA) (13). According to this rule, in Sweden, 712 of 784 
(90.8 %) DILI patients with jaundice recovered, and 72 
(9.2 %) died or underwent liver transplant surgery. Women 
are generally considered more at risk of DILI (18). 
The classification of drug induced hepatotoxicity
DILI covers a variety of types and contains most of the 
clinical and pathological expressions of liver damage. 
Figure 1 shows drug-induced hepatotoxicity types (19). 
Statins are generally used for hyperlipidaemia. They 
competitively inhibit 3-hydroxy-3-methylglutarylcoenzyme 
A (HMG-CoA) reductase that is necessary for cholesterol 
biosynthesis. Statins play important roles via several ways 
in decreasing the level of low density lipoproteins (LDLs) 
and increasing the stability of atherosclerotic plaques. 
Therefore, they are effective in reducing cardiovascular 
mortality. According to the PubMed database, researchers 
are widely focused on six statins. These statins are presented 
in Figure 2 (19-23).
In the USA, in a DILI study, the longest-term study 
carried out on statins, statins were prescribed for patients 
with hyperlipidaemia. It was found that these were generally 
well tolerated. Small elevations in serum ALT and aspartate 
aminotransferase (AST) were observed (up to 3 % of treated 
patients), but clinically DILI was rare. Of 1,188 cases of 
DILI enrolled between 2004 and 2012 in a prospective 
registry by the U.S. DILI Network, 22 cases were attributed 
to statins. The latency period to the onset of liver injury 
ranged from 34 days to 10 years. Median peak levels were 
892 U L-1 for serum ALT, 358 U L-1 for alkaline phosphatase 
(AP), and 6.1 mg dL-1 for total bilirubin. Nine patients had 
cholestatic hepatitis and 12 patients had hepatocellular 
injury, of which six had an autoimmune phenotype. Nine 
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patients were hospitalised, four patients developed hepatic 
failure, and one died (24).
Hepatic toxicity/injury mechanism/s of statins
So far, different hepatotoxicity mechanisms have been 
proposed, some of which have been completely explained. 
However, most hepatotoxicity mechanisms have not been 
entirely understood and therefore researchers keep 
conducting studies. The present review focused on statin 
induced hepatotoxicity and possible hepatotoxicity 
mechanisms. Many observational studies in North America 
and Europe have confirmed that there are inconsistent 
results on the unintended effects of statins. Statins are 
related to lower risks of dementia and cognitive impairment, 
venous thromboembolism, fractures and pneumonia while 
they have not been related to any increased risk of 
depression, arthritis, renal disorders, or common eye 
diseases. However, it is well known that statins increase 
liver enzymes, risk of myopathy, and risk of diabetes 
mellitus (DM) (25). The most common complications 
related to statins are hepatotoxicity and myopathy. 
Hepatotoxicity and myopathy occur with the use of statins 
and the incidence of these effects increases when these are 
used; 
i. at maximum doses 
ii. together with other lipid lowering drugs such as 
fibrates (drug-drug interaction) 
iii. with drugs which use the same enzymatic pathway 
such as some cytochrome P450 enzymes 
iv. by elderly subjects and subjects having considerable 
hepatic and/or renal dysfunction (26).
Animal experiments revealed that liver toxicity not 
observed at therapeutic doses was seen at higher doses of 
statins. High doses of lovastatin in rabbits and simvastatin 
in guinea pigs caused necrosis in hepatic cells (21). The 
liver injury in these animals can be prevented or reversed 
by mevalonate reinforcement since the consumption of 
mevalonate or its downstream metabolites may be 
responsible for the injury (27).
The main biomarkers of liver abnormalities are 
aminotransferases. Different liver abnormalities are listed 
below according to the levels of aminotransferases;
i. Asymptomatic elevations of ALT) (generally moderate 
and temporary; ALT <3 × ULN), 
ii. Hepatitis: with ALT >3 × ULN and clinical symptoms 
of liver injury,
iii. Cholestatic or mixed hepatitis: with improvement 
of icterus
iv. Autoantibody associated DILI with presence of 
antinuclear antibody (ANA) and antismooth muscle 
antibody (AMA) or antimitochondrial antibody (AMiA) 
with or without plasma cells upon liver biopsy.  ALF does 
not improve in majority of subjects who use statins (28).
The exact mechanism by which statins cause liver injury 
is not well understood (29). Mitochondrial dysfunction is 
one of the major factors that explain the mechanism of 
statin-induced hepatotoxicity. The dose- and time-
dependent impairment of mitochondrial function by statins 
was shown in in vitro models. After statin treatment, there 
has been a significant increase in mitochondrial superoxide, 
which is determined by the mitochondrial toxicity assay. 
This increase leads to significant mitochondrial impairment. 
Another major reason for statin induced hepatotoxicity is 
that statins cause apoptotic cell death. In particular, 
cerivastatin was withdrawn from the market in 2001 due to 
DILI (30). Other possible hepatotoxicity mechanisms are 
the inhibition of the respiratory chain (complex I and III), 
depolarisation of mitochondrial membrane, and release of 
Ca+2.
Drugs are metabolised by the liver cytochrome P450 
enzymes. These enzymes include a super -family of 
monooxygenases. Their members can be of critical function 
for the catabolism of xenobiotics. Mitochondria or 
cytochrome P450-dependent metabolism act as Reactive 
Oxygen Species (ROS) generation systems and participate 
in cell death processes. In the use of statins, hepatocytes 
produce a significant amount of ROS. They cause lipid 
peroxidation, thus leading to a decrease in the mitochondrial 
membrane potential and promoting cytotoxicity. All these 
Figure 1 Drug-induced hepatotoxicity types; *ADME-Absorption, distribution, metabolism, and excretion
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effects are dose-and time-dependent although data are not 
shown at different doses of statins. The highest amount of 
ROS is produced by simvastatin (29). On the other hand, 
clinical trials have shown that the levels of ALT were higher 
in about 3 % of subjects who received these drugs. However, 
such elevations are clinically insignificant in great majority 
of cases; indeed, the levels of ALT were greater than three 
times the ULN, but this was not seen in the majority of 
patients and when statins were in continuous use. This 
phenomenon, first the elevations in aminotransferases and 
then return to normal levels, is called adaptation, but it is 
not a well understood mechanism. This phenomenon is 
observed in a number of drugs, such as antidepressants 
(olanzapine) (28, 31). The cause of asymptomatic 
aminotransferase elevation caused by statins is unknown. 
One of speculations is that increased aminotransferases may 
actually arise from a pharmacodynamic effect of general 
lipid lowering drugs. This explanation may be plausible 
since the increased level of aminotransferases occur, with 
all lipid-lowering agents, not only statins, including 
ezetimibine that has no effect on hepatic cholesterol 
synthesis or bile acid excretion. Clinically significant liver 
injury by statins may be caused via idiosyncratic and 
immunoallergic mechanisms (27). In another study, it has 
been indicated that lactic acidosis plays an important role 
in the toxicity of statins. There is no evidence that lactic 
acidosis is an additive side effect or that it causes 
mitochondrial dysfunction (32).
Case-control studies on statins
There have been many published studies on the 
hepatotoxicity of statins. Statin group drugs are one of the 
best examples of difficulties encountered in attempting to 
strike the right benefit and risk balance with regard to DILI. 
Actually, the frequency of liver injury by statins is estimated 
to be 1 in 100 000 patient-years. About 3 % of patients who 
receive statin treatment experience an increase in 
aminotransaminases, but this increase typically normalises 
with continuous use. There are various studies on the safety 
of statins in patients with chronic liver disease. Statins can 
cause cholestatic and hepatocellular injury, rarely severe or 
fatal though. It is necessary to find a biomarker or any other 
tool for identifying the risk of DILI, also due to other 
commonly used drugs, not only statins (33).
There has been no evidence to support the cause and 
effect relationship for many other adverse effects. For 
example, in a well-designated long-term controlled follow-
up study, patients (n=170,000) showed that statins had no 
effect on liver disease, cancer, dementia, kidney disease, 
cerebral haemorrhages, memory impairment, or fatigue. 
Although liver function test (LFT) may be outside the 
normal range of 0.1 % to 3 % in subjects receiving higher 
doses of statins, when the statins are stopped, the tests return 
to this normal range. Permanent liver damage is extremely 
rare. Treatment with statins is associated with the diagnosis 
of new onset diabetes mellitus (DM).  However, this risk 
is very low and statin therapy is preferred due to its benefits 
(34). 
In another study, known as statin-induced liver injury 
(SILI) study, 108 cases and 324 controls were examined. 
The results showed that clinically significant elevations of 
liver enzymes were observed in four years. Most of the 
subjects in the case group were treated with high doses of 
different statins. There were no statistically significant 
differences in gender, age, LFT, type of liver injury, latency 
and severity, and Hepatitis B Virus (HBV) status (35).
Meta analyses on statins
Denus et al. (36) identified 13 meta-analyses of 
randomised, placebo-controlled studies. They investigated 
LFT abnormalities when four statins were used: lovastatin, 
simvastatin, pravastatin, fluvastatin. Only the 48-week trials 
were chosen because all these drugs are used in long-term 
treatments (37). Serum ALT and AST levels were used as 
the biomarker of liver injury in this meta-analysis and ALT 
was more deterministic than AST (38, 39). They concluded 
that placebo and statins gave similar results. However, LFT 
abnormalities were observed only for fluvastatin (fluvastatin 
1.13 % vs. placebo 0.29 %, OR= 3.54, 95 % CI=1.1–11.6, 
p=0.04). They concluded that LFT abnormalities of 
fluvastatin were about three times higher than placebo due 
to CYP2C9 gene polymorphisms (40, 41). The variability 
of LFT abnormalities among the studies examined showed 
an inconsistency between fluvastatin and the results on other 
statins. They stated that low-moderate doses of pravastatin, 
lovastatin, and simvastatin did not cause a major risk with 
regard to LFT abnormalities (36). Genetic polymorphisms 
or individual susceptibility to drugs has become an 
important issue for drugs after the Human Genome Project 
(HGP), which was completed in 2000. After HGP, it was 
revealed that genetic makeup had a major impact on the 
pharmacological and toxicological effects of drugs. 
Especially, genetic polymorphisms in metabolising 
enzymes have a major impact on the statin-induced 
Figure 2 The six most commonly studied statins
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hepatotoxicity. Due to genetic polymorphisms, LFT 
abnormalities were frequently observed in statin treatments. 
Simvastatin is metabolised primarily by CYP3A4, when it 
is used concomitantly with amiodarone, which is an 
inhibitor of CYP3A4 enzyme; and interaction between these 
two drugs (simvastatin and amiodarone) increases 
hepatotoxicity (42). Another study, meta-analysis was 
carried out by Zhong et al. (43). They investigated the 
protective effects of statins relative to the risk of primary 
liver cancer. They searched all studies from PubMed and 
EMBASE databases. Risk ratios of six statins (lovastatin, 
simvastatin, pravastatin, fluvastatin, atorvastatin, 
rosuvastatin) were evaluated. They concluded that the use 
of statins decreased the risk of primary liver cancer. Notably, 
the protective effects of rosuvastatin were higher than those 
of the other statins (43).
Epidemiological studies on statins
A study involving a cohort of 185 patients who were 
treated with statins was conducted. Among these patients, 
only 2 % had a previous chronic liver disease. At clinical 
presentation, 57.8 % showed a hepatocellular pattern, 
18.3 % a cholestatic, and 23.2 % a mixed one. Statins were 
involved in 4.3 % of cases and were not frequently 
responsible for chronicity (44). DILI secondary to statins 
was investigated in Sweden by Bjornsson et al. (45).  The 
Swedish Adverse Reactions Advisory Committee captured 
all spontaneously reported adverse reactions thought to be 
related to statins (1988-2010). Of 217 cases of all types of 
adverse events related to statins, 73 patients were identified 
to have a possible DILI. Seventy-one percent of liver injury 
cases were considered possibly related to statins, 19 % were 
probable, and 10 % highly probable. According to this study, 
statins can cause serious IDRs, but this remains an 
extremely rare phenomenon estimated to be observed in 
1.6 cases per 100,000 person-years of use (46). 
Among 1,188 cases of DILI enrolled between 2004 and 
2012 in a prospective registry by the U.S. DILI Network, 
22 were attributed to a statin. All patients were evaluated 
in a standard fashion and followed for at least six months 
after the onset. Nine patients developed cholestatic hepatitis 
and 12 patients hepatocellular injury, of which six had an 
autoimmune phenotype. Nine patients were hospitalised, 
four developed evidence of hepatic failure, and one died. 
All commonly used statins were implicated. Four patients 
developed chronic liver injury, of which three had an 
autoimmune phenotype of liver injury. Thus, DILI 
from statins is rare and characterised by variable patterns 
of injury, a range of latencies to onset, autoimmune features 
in some cases, and a persistent or chronic injury in 18 % of 
patients, most of whom had the autoimmune phenotype 
(24).
In a large proportion of DILI reports, concomitant 
hepatotoxic and/or interacting drugs were recorded: 42 % 
and 37 % (rivaroxaban and dabigatran, respectively), 
especially statins, paracetamol and amiodarone (47). A 
prospective population-based study found a rough incidence 
of approximately 19 DILI cases per 100,000 and year. 
Although rare, statin-induced hepatotoxicity has been well 
documented (48). DILI from statins typically presents with 
an acute hepatocellular liver injury pattern, although mixed 
or cholestatic injury patterns have also been reported. 
Despite their widespread use, acute liver failure and death 
have rarely been reported in patients with statin hepatotoxicity. 
Multiple retrospective studies, as well as one large 
prospective randomised controlled trial demonstrate 
that statins can safely be given to hyperlipidaemic patients 
with compensated chronic liver disease (49).
Charles et al. (50) aimed to describe the rate, potential 
causes, symptoms, time to onset, and time to resolution of 
severe transaminitis associated with statin. ALT and AST 
had never been measured in 9 % of eligible patients. In the 
remaining patients, 0.3 %, were identified with an ALT 
greater than 10 times the ULN. Of these, 17 (0.1 %) had 
severe transaminitis deemed directly attributable to statin 
use. In 16 cases, transaminitis resolved upon statin 
discontinuation. In this study, statin-related severe 
transaminitis occurred infrequently. These findings support 
less frequent liver enzyme monitoring for most patients 
on statins (50). 
In the period 1994-2012, the Spanish Hepatotoxicity 
Registry recorded a total of 858 cases, 47 (5.5 %) of which 
were attributed to statins. Of these, 34 % were due to 
atorvastatin, 27.7 % to simvastatin, 25.5 % to fluvastatin, 
8.5 % to lovastatin, and 4.3 % to pravastatin. The 
hepatocellular pattern was predominant, especially in the 
simvastatin group (85 %), the cholestatic/mixed pattern was 
more frequent with fluvastatin (66 %) and had a similar 
distribution to that of atorvastatin. In conclusion, statins are 
not a common cause of hepatotoxicity. The liver injury 
pattern varies among different statins. The hepatitis 
phenotype with autoimmune features appears to be a 
characteristic signature of the statin-induced hepatotoxicity 
(51).
A nationwide population-based cohort study was 
conducted by the Taiwan National Health Insurance 
database. A total of 37,929 subjects with chronic liver 
disease who were on statin therapy were identified during 
2005-2009. The outcome was defined as hospitalisation due 
to the liver injury. The overall incidence of hospitalisation 
due to severe hepatic injury was low among statin initiators 
with chronic liver disease. Only high-dose atorvastatin was 
associated with increased risk (52). Younoszai et al. (53) 
used the Third National Health and Nutrition Examination 
Survey (NHANES III)-mortality linked files to assess the 
association between statin use and liver-related mortality. 
Of all adult NHANES III participants enrolled in 1988-1994 
(n=20,050), 9,207 individuals had sufficient demographic, 
clinical, and medical information making them eligible for 
this study. In this survey, the rate of liver-related mortality 
was significantly lower (p=0.0035) among statin users 
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compared to non-statin users. After a decade of follow up, 
there was no association between statin use and liver-related 
mortality (53). Despite their widespread use, statins are an 
uncommon cause of idiosyncratic DILI. Recent studies have 
shown that statins are actually safe and efficacious to be 
used in hyperlipidaemic patients with chronic liver disease 
(54). Statins rarely cause significant liver injury whereas 
antiretroviral therapy is associated with hepatotoxicity in 
10 % of treated patients (55). 
CONCLUSION
Statins are extremely valuable in the treatment of human 
diseases and they have a widespread usage. There are many 
studies made on the hepatotoxicities of statins as well as 
other adverse effects such as cardiovascular disease, DM, 
and cancer risk. Epidemiological studies, since they are 
carried out on humans, are more valuable than individual 
studies and meta-analyses. In this review, conclusion is 
based on the most reliable and valuable study groups. The 
other major issue in the evaluation of the hepatotoxicity of 
statins is individual susceptibility to statins. Genetic 
polymorphism, notably of metabolising enzymes, has a 
major role in the hepatotoxicity of statins such as fluvastatin. 
Differences in the hepatotoxicity of statins are also observed 
among populations such as Spain and Taiwan. Drug-drug 
interactions also increase the hepatotoxicity of statins. The 
available data indicate that statins are not frequently 
responsible for liver injury, but there are several issues 
related to their usage in humans that require further research. 
More studies should be conducted to evaluate the 
pharmacokinetics of different statins at various doses, 
prolonged use of statins and long-term effects of statins on 
hepatic histology, and genetic polymorphisms. Finally, the 
current recommendations regarding liver biochemistry 
monitoring before and during statin therapy are not 
necessarily meaningful and they need to be re-examined 
by health sector employees.
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Hepatotoksičnost povezana sa statinima
Terapija statinima opće je prihvaćena diljem svijeta i njihove se terapijske doze općenito smatraju sigurnima. Ipak, klinička 
ispitivanja nisu dostatna kako bi se procijenile rijetke nuspojave primjene statina, poput idiosinkratske lijekom izazvane 
ozljede jetara (drug induced liver injury – DILI). Zbog nekih stanja poput istodobne uporabe određenih lijekova (interakcija 
dvaju lijekova koji imaju isti metabolizirajući enzim) i genskih polimorfizama, javlja se određena zabrinutost u vezi s 
njihovom sigurnom primjenom. U brojnim se studijama kao nuspojave primjene statina navode hepatotoksičnost i 
rabdomioliza. Većina istraživanja usredotočena je na nuspojave i mehanizme lijekom izazvane toksičnosti. U ovom se 
preglednom radu nastoje sažeti gotovo sve postojeće studije o hepatotoksičnosti statina, ali ne i o rabdomiolizi. Cilj je 
ponuditi pregled istraživanja hepatotoksičnosti koja je povezana s uporabom statina te razraditi objavljene rezultate tih 
istraživanja. Istraživači su mišljenja da je istraživanje ovoga problema nepotpuno ali prijeko potrebno.
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